Search

Your search keyword '"Neulasta (Medication)"' showing total 27 results
Start Over Descriptor "Neulasta (Medication)" Publisher plus media
27 results on '"Neulasta (Medication)"'

1. BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release|Media Release (Update on 25-09-18)

Subjects
United States. Food and Drug Administration -- Laws, regulations and rules, Drug approval -- Laws, regulations and rules, Government regulation, General interest, News, opinion and commentary, Neulasta (Medication), Fulphila (Medication)
Abstract

Mumbai: U.S. FDA approves Mylan and Biocon's Fulphila (pegfilgrastim-jmdb), the first Biosimilar to Neulasta(r) -Press Release The full document can be viewed at the following link: [...]

Published
2018

2. Coherus BioSciences Reports Corporate Highlights and Second Quarter 2018 Financial Results

Subjects
United States. Food and Drug Administration, Biotechnology industries -- Company sales and earnings, Company earnings/profit, General interest, News, opinion and commentary, Neulasta (Medication)
Abstract

California: Coherus BioSciences, Inc. has issued the following press release: Coherus BioSciences, Inc. (Nasdaq: CHRS), today reviewed corporate highlights and reported financial results for the quarter ended June 30, 2018. [...]

Published
2018

3. Vizient Commends the FDA on Its Recent Approval of the First Neulasta Biosimilar

Subjects
United States. Food and Drug Administration, General interest, News, opinion and commentary, Neulasta (Medication)
Abstract

IRVING: Vizient, Inc. has issued the following press release: Vizient today applauds the U.S. Food and Drug Administration (FDA) on its announcement yesterday that it approved the first biosimilar to [...]

Published
2018

4. Biocon bags USFDA approval for Neulasta(r)

Subjects
United States. Food and Drug Administration, Drug approval, General interest, News, opinion and commentary, Neulasta (Medication), Fulphila (Medication)
Abstract

Mumbai: Indsec Securities & Finance Ltd has issued the following press release: Biocon Ltd. has said that the U.S. Food and Drug Administration (FDA) has approved Mylan's FulphilaTM (pegfilgrastim-jmbd), a [...]

Published
2018

5. Biocon - Announcement under Regulation 30 (LODR)-Press Release|Media Release

Subjects
United States. Food and Drug Administration -- Laws, regulations and rules, Drug approval -- Laws, regulations and rules, Government regulation, General interest, News, opinion and commentary, Neulasta (Medication), Fulphila (Medication)
Abstract

Mumbai: Indsec Securities and Finance Ltd. (Indsec) has issued the following news release: U.S. FDA approves Mylan and Biocon's Fulphila (pegfilgrastim-jmdb), the first Biosimilar to Neulasta(r) -Press [...]

Published
2018

6. U.S. FDA Approves Mylan and Biocon's Fulphila (pegfilgrastim-jmdb), the First Biosimilar to Neulasta(r)

Subjects
United States. Food and Drug Administration, Mylan N.V., Cancer treatment, Pharmaceutical industry, Drug approval, General interest, News, opinion and commentary, Neulasta (Medication), Fulphila (Medication)
Abstract

Netherlands: MYLAN N.V. has issued the following press release: Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U.S. Food and Drug Administration [...]

Published
2018

7. Coherus BioSciences Re-Submits Biologics License Application for CHS-1701 (Pegfilgrastim Biosimilar Candidate)

Subjects
Coherent Inc., Biotechnology industries, Laser industry, General interest, News, opinion and commentary, Neulasta (Medication)
Abstract

Redwood City: Coherent Inc. (COHR) has issued the following press release: Coherus BioSciences, Inc. (NASDAQ:CHRS), today announced the re-submission of its biologics license application (BLA) for CHS-1701, a pegfilgrastim (Neulasta(r)) [...]

Published
2018

8. Amgen Reports First Quarter 2018 Financial Results

Subjects
Amgen Inc., Biotechnology industries, General interest, News, opinion and commentary, Prolia (Medication), Repatha (Medication), Xgeva (Medication), Neulasta (Medication)
Abstract

United States: AMGEN INC. has issued the following press release: Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2018. Key results include: Total revenues increased 2 percent [...]

Published
2018

10. BeyondSpring Presents Promising Data for Lead Asset Plinabulin at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Subjects
Conferences and conventions -- Conferences, meetings and seminars, Chemotherapy -- Conferences, meetings and seminars, Medical research -- Conferences, meetings and seminars, General interest, News, opinion and commentary, Neulasta (Medication)
Abstract

NEW YORK : BeyondSpring Inc has issued the following press release: BeyondSpring Inc. (NASDAQ:BYSI), a global clinical-stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, announced that [...]

Published
2018

11. BeyondSpring Presents Promising Data for Lead Asset Plinabulin at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Subjects
Conferences and conventions -- Conferences, meetings and seminars, Chemotherapy -- Conferences, meetings and seminars, Medical research -- Conferences, meetings and seminars, General interest, News, opinion and commentary, Neulasta (Medication)
Abstract

New York: BeyondSpring Inc. has issued the following press release: BeyondSpring Inc. (NASDAQ:BYSI), a global clinical-stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, announced that the [...]

Published
2018

12. BeyondSpring to Present Data from Phase 2 Portion of Study 105 Phase 2|3 Trial with Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Subjects
Clinical trials, Chemotherapy, Medical research, Neutropenia, Docetaxel, General interest, News, opinion and commentary, Neulasta (Medication)
Abstract

New York: BeyondSpring Inc. has issued the following press release: BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced [...]

Published
2018

13. Amgen Financial Reports: Amgen's First Quarter 2014 Revenues Increased 7 Percent To $4.5 Billion

Subjects
Amgen Inc. -- Company sales and earnings, Onyx Pharmaceuticals Inc. -- Company sales and earnings, Biotechnology industries -- Company sales and earnings, Biological products industry -- Company sales and earnings, Company earnings/profit, General interest, News, opinion and commentary, Prolia (Medication), Enbrel (Medication), Xgeva (Medication), Neulasta (Medication)
Abstract

Thousand Oaks: Amgen has issued the following First Quarter 2014 : Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2014. Key results include: Total revenues increased 7 [...]

Published
2017

14. Amgen Financial Reports: Amgen's Third Quarter 2014 Revenues Increased 6 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 19 Percent To $2.30

Subjects
Amgen Inc. -- Company sales and earnings, Biotechnology industries -- Company sales and earnings, Company earnings/profit, General interest, News, opinion and commentary, Prolia (Medication), Xgeva (Medication), Neulasta (Medication), Neupogen (Medication)
Abstract

Thousand Oaks: Amgen has issued the following Third Quarter 2014 : Amgen (NASDAQ: AMGN) today announced financial results for the third quarter of 2014. Key results include: Total revenues increased [...]

Published
2017

15. Amgen Financial Reports: Amgen's Third Quarter 2015 Revenues Increased 14 Percent To $5.7 Billion And Adjusted Earnings Per Share (EPS) Increased 18 Percent To $2.72

Subjects
Amgen Inc. -- Company sales and earnings, Biotechnology industries -- Company sales and earnings, Company earnings/profit, General interest, News, opinion and commentary, Prolia (Medication), Sensipar (Medication), Enbrel (Medication), Repatha (Medication), Xgeva (Medication), Neulasta (Medication)
Abstract

Thousand Oaks: Amgen has issued the following Third Quarter 2015 Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2015. Key results include: Total revenues increased 14 percent [...]

Published
2017

16. Amgen Financial Reports: Amgen's First Quarter 2016 Revenues Increased 10 Percent To $5.5 Billion And Adjusted Earnings Per Share (EPS) Increased 17 Percent To $2.90

Subjects
Amgen Inc., Biotechnology industries, General interest, News, opinion and commentary, Aranesp (Medication), Prolia (Medication), Enbrel (Medication), Xgeva (Medication), Neulasta (Medication)
Abstract

Thousand Oaks: Amgen has issued the following First Quarter 2016 : Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2016. Key results include: Total revenues increased 10 [...]

Published
2017

17. Award-Winning Journalist And Cancer Survivor Joan Lunden Partners With Amgen To Launch 'At Home With Joan' To Empower Patients Battling Cancer

Subjects
Amgen Inc., Journalists, Cancer, Chemotherapy, Biotechnology industries, Cancer patients, General interest, News, opinion and commentary, Neulasta (Medication)
Abstract

Dublin: Amgen Inc. has issued the following press release: -- Amgen (NASDAQ:AMGN) today announced the launch of At Home with Joan, a campaign led by breast cancer survivor and advocate [...]

Published
2017

18. Agenda - PRAC draft agenda of meeting 29 August-1 September 2017

Subjects
Bayer AG, Pfizer Inc., Bristol-Myers Squibb Co., Boehringer Ingelheim GmbH, Merck Sharp & Dohme Ltd., AstraZeneca PLC, UCB Pharma S.A., Pfizer Ltd., Pharmaceutical industry, Risk assessment, Business, international, European Union, European Union. European Commission, Exjade (Medication), Nuwiq (Medication), Yervoy (Medication), Inflectra (Medication), Humalog (Medication), Zepatier (Medication), Neulasta (Medication)
Abstract

London: European Medicine Agency has issued the following new product details: 30 Churchill Place * Canary Wharf * London E14 5EU * United Kingdom An agency of the European Union [...]

Published
2017

19. Amgen Launches Neulasta(r) (pegfilgrastim) Onpro(r) NARRATIVES

Subjects
Chemotherapy, General interest, News, opinion and commentary, Neulasta (Medication)
Abstract

California: Amgen has issued the following news release: Amgen (NASDAQ: AMGN) today announced the launch of Neulasta(r) (pegfilgrastim) Onpro(r) NARRATIVES, an online media resource about the value of a cancer [...]

Published
2017

20. Neulasta pegfilgrastim

Subjects
Business, international, Neulasta (Medication)
Abstract

London: European Medicine Agency has issued the following news release: This is a summary of the European public assessment report (EPAR) for Neulasta. It explains how the Committee for Medicinal [...]

Published
2017

21. U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Pegfilgrastim for Review

Subjects
United States. Food and Drug Administration, Mylan N.V., Chemotherapy, Pharmaceutical industry, General interest, News, opinion and commentary, Neulasta (Medication)
Abstract

Canonsburg: Mylan N.V. has issued the following press release: Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U.S. Food and Drug [...]

Published
2017

22. U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Pegfilgrastim for Review

Subjects
United States. Food and Drug Administration, Mylan N.V., Chemotherapy, Pharmaceutical industry, General interest, News, opinion and commentary, Neulasta (Medication)
Abstract

Amsterdam: Mylan N.V has issued the following news release: Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U.S. Food and Drug [...]

Published
2017

23. U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Pegfilgrastim for Review

Subjects
United States. Food and Drug Administration, Mylan N.V., Pharmaceutical industry, General interest, News, opinion and commentary, Neulasta (Medication)
Abstract

Amsterdam: Mylan N.V has issued the following news release: HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India, Feb. 16, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: [...]

Published
2017

25. Coherus BioSciences Announces FDA Acceptance of 351(k) Biologics License Application to U.S. Food and Drug Administration for CHS-1701 (Pegfilgrastim Biosimilar Candidate)

Subjects
United States. Food and Drug Administration, Biotechnology industries, General interest, News, opinion and commentary, Neulasta (Medication)
Abstract

Redwood City: Coherus BioSciences, Inc. has issued the following press release: Coherus BioSciences, Inc. (NASDAQ:CHRS), a leading pure-play, global biosimilar company with late-stage clinical products, today announced that the U.S. [...]

Published
2016

26. Apotex Announces FDA Has Accepted For Filing its Biosimilar Application for Pegfilgrastim

Subjects
United States. Food and Drug Administration, Apotex Inc., Pharmaceutical industry, General interest, News, opinion and commentary, Neulasta (Medication)
Abstract

Ontario, Canada: Apotex, Inc has issued the following news release: Apotex Inc., the largest Canadian owned pharmaceutical company, announced today that the US Food and Drug Administration has accepted for [...]

Published
2016

27. Coherus BioSciences Submits 351(k) Biologics License Application to U.S. Food and Drug Administration for CHS-1701 (Pegfilgrastim Biosimilar Candidate)

Subjects
Biotechnology industries, General interest, News, opinion and commentary, Neulasta (Medication)
Abstract

Redwood City: Coherus BioSciences, Inc. has issued the following press release: Coherus BioSciences, Inc. (NASDAQ:CHRS), today announced submission of the biologics license application (BLA) for CHS-1701, a pegfilgrastim (Neulasta(r)) biosimilar [...]

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results